ArticleJournal of translational medicine2026
Hybrid bioinspired nanovescicles target tumor endothelial cells and regulate immuno-microenvironment for triple-negative breast cancer therapy.
Article in Journal of translational medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundThe treatment of triple-negative breast cancer (TNBC) remains challenging. Conventional anti-angiogenic therapies, which aim to disrupt the tumor’s blood supply, are often hampered by limited efficacy and drug resistance. Innovative strategies that specifically target the unique phenotype of tumor vascular endothelial cells (TVECs) are urgently needed.
methodsWe developed peroxide-treated hybrid membrane bio-nanovesicles (ox-HyV) by fusing membranes from human induced pluripotent stem cell-derived endothelial cells (iPSC-ECs) and breast cancer cells. The vesicles were characterized for size, morphology, and protein composition. Their targeting efficiency to TVECs was validated both in vitro and in vivo using immunofluorescence and small animal imaging. The functional effects on TVEC secretion, cGAS-STING pathway activation, and immune cell recruitment were assessed via ELISA, western blot, flow cytometry, and immunofluorescence. The anti-tumor efficacy and survival benefit were evaluated in a murine TNBC model.
resultsox-HyVs specifically targeted and were internalized by TVECs. They reprogrammed the secretory phenotype of TVECs by delivering key molecular cargoes, notably miR-429, which subsequently downregulated Bcl2 and activated the cGAS-STING pathway. This activation triggered a robust innate immune response and promoted the infiltration of cytotoxic T cells into tumors. In vivo, treatment with ox-HyVs significantly inhibited tumor growth and extended survival in a TNBC mouse model.
conclusionWe have developed a novel bio-nanovesicle, ox-HyV, that represents a significant advancement over previous hybrid membrane systems. Unlike conventional hybrid vesicles designed primarily for drug delivery, ox-HyV is engineered through peroxidation to be intrinsically immunogenic, enabling it to directly reprogram the tumor vasculature and activate the cGAS-STING pathway via its endogenous miRNA cargo. This self-adjuvating, multimodal mechanism effectively converts the immunosuppressive tumor microenvironment into an immunoreactive one. Our study not only presents a potent new therapeutic candidate but also establishes a broadly applicable platform technology for vascular-targeted immunotherapy, with strong promise for clinical translation in TNBC and other solid tumors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.